BOLTON SECURITIES CORPORATION’s Neumora Therapeutics NMRA Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$798	Buy	+798	New	+$1.37K	﹤0.01%	1795

Other funds holding NMRA

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.74% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $714M AUM 64.22% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's NMRA Position: Q1 2025 in Review

BOLTON SECURITIES CORPORATION opened a new position in Neumora Therapeutics (NMRA) in Q1 2025: 798 shares worth $798. The stake represents ﹤0.01% of the portfolio and ranks #1795 among its holdings.

116 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

BOLTON SECURITIES CORPORATION held 798 shares of Neumora Therapeutics worth $798 as of Q1 2025.
Neumora Therapeutics was a new BOLTON SECURITIES CORPORATION position in Q1 2025.
Neumora Therapeutics made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q1 2025, its #1795 holding.
116 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q1 2025, filed 12 Nov 2026.